KR101886879B1 - Ｐｂｒ 리간드로서의 트리시클릭 인돌 유도체 - Google Patents

Ｐｂｒ 리간드로서의 트리시클릭 인돌 유도체 Download PDF

Info

Publication number
KR101886879B1
KR101886879B1 KR1020127025137A KR20127025137A KR101886879B1 KR 101886879 B1 KR101886879 B1 KR 101886879B1 KR 1020127025137 A KR1020127025137 A KR 1020127025137A KR 20127025137 A KR20127025137 A KR 20127025137A KR 101886879 B1 KR101886879 B1 KR 101886879B1
Authority
KR
South Korea
Prior art keywords
formula
compound
iii
pet
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127025137A
Other languages
English (en)
Korean (ko)
Other versions
KR20130018711A (ko
Inventor
라다 아차나쓰
스리나쓰 발라지
스티븐 마이클 페어웨이
디미트리오스 만칠라스
우마마헤슈와르 모카파티
데니스 오'쉐어
조안나 마리 패스모어
보 산
윌리엄 존 트리그
해리 존 와즈워쓰
아프잘 모하메드 카다빌프파람푸 모하메드
Original Assignee
지이 헬쓰케어 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/053998 external-priority patent/WO2010109007A2/en
Priority claimed from GBGB1015203.1A external-priority patent/GB201015203D0/en
Application filed by 지이 헬쓰케어 리미티드 filed Critical 지이 헬쓰케어 리미티드
Publication of KR20130018711A publication Critical patent/KR20130018711A/ko
Application granted granted Critical
Publication of KR101886879B1 publication Critical patent/KR101886879B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020127025137A 2010-03-26 2011-03-28 Ｐｂｒ 리간드로서의 트리시클릭 인돌 유도체 Active KR101886879B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EPPCT/EP2010/053998 2010-03-26
PCT/EP2010/053998 WO2010109007A2 (en) 2009-03-27 2010-03-26 Indole derivatives
IN1824/DEL/2010 2010-08-02
IN1824DE2010 2010-08-02
US12/880,218 2010-09-13
GBGB1015203.1A GB201015203D0 (en) 2010-03-26 2010-09-13 Active enantiomer
US12/880,218 US8501153B2 (en) 2009-03-27 2010-09-13 Active enantiomer
GB1015203.1 2010-09-13
PCT/EP2011/054744 WO2011117421A1 (en) 2010-03-26 2011-03-28 Tricyclic indole derivatives as pbr ligands

Publications (2)

Publication Number Publication Date
KR20130018711A KR20130018711A (ko) 2013-02-25
KR101886879B1 true KR101886879B1 (ko) 2018-08-08

Family

ID=44259848

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127025137A Active KR101886879B1 (ko) 2010-03-26 2011-03-28 Ｐｂｒ 리간드로서의 트리시클릭 인돌 유도체

Country Status (15)

Country Link
EP (1) EP2552891B1 (enExample)
JP (1) JP5830519B2 (enExample)
KR (1) KR101886879B1 (enExample)
CN (1) CN102834379B (enExample)
AU (1) AU2011231508B2 (enExample)
BR (1) BR112012021579A2 (enExample)
CA (1) CA2792394C (enExample)
ES (1) ES2688574T3 (enExample)
IL (1) IL221510A (enExample)
MX (1) MX2012010954A (enExample)
NZ (1) NZ602025A (enExample)
RU (1) RU2551423C2 (enExample)
SG (1) SG183837A1 (enExample)
WO (1) WO2011117421A1 (enExample)
ZA (1) ZA201208067B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2946159B2 (ja) 1993-04-01 1999-09-06 高浜工業株式会社 瓦焼成用のスペ−サ装着装置
GB201016038D0 (en) * 2010-09-24 2010-11-10 Ge Healthcare Ltd In vivo imaging method
GB201016411D0 (en) 2010-09-30 2010-11-10 Ge Healthcare Ltd In vivo imaging method for cancer
BR112015012138A2 (pt) * 2012-11-30 2017-07-11 Ge Healthcare Ltd composição, método para obtenção de uma composição, método de formação de imagem in vivo, e, kit
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
GB201316764D0 (en) * 2013-09-20 2013-11-06 Ge Healthcare Ltd Novel compounds
US10660966B2 (en) 2014-12-04 2020-05-26 Ge Healthcare Limited Method for removing acetaldehyde
CN106748802B (zh) * 2016-12-26 2018-11-13 南京理工大学 一种制备含氟仲胺的方法
CN114085221B (zh) * 2021-11-29 2022-12-09 暨南大学 含氮杂环化合物、标记的含氮杂环化合物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044751A1 (fr) 1999-01-26 2000-08-03 Sanofi-Synthelabo DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2007057705A1 (en) 2005-11-18 2007-05-24 Hammersmith Imanet Limited Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US7160909B2 (en) 2001-08-09 2007-01-09 Eli Lilly And Company Cyclopenta[b]indole derivatives as sPLA2 inhibitors
BRPI0716583A2 (pt) * 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044751A1 (fr) 1999-01-26 2000-08-03 Sanofi-Synthelabo DERIVES DE 4-OXO-3,5-DIHYDRO-4H-PYRIDAZINO[4,5-b]INDOLE-1-CARBOXAMIDE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2007057705A1 (en) 2005-11-18 2007-05-24 Hammersmith Imanet Limited Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (pbr)

Also Published As

Publication number Publication date
RU2012141697A (ru) 2014-05-10
NZ602025A (en) 2014-08-29
CA2792394C (en) 2018-04-24
AU2011231508A1 (en) 2012-10-04
KR20130018711A (ko) 2013-02-25
CN102834379B (zh) 2014-12-24
EP2552891A1 (en) 2013-02-06
CA2792394A1 (en) 2011-09-29
WO2011117421A1 (en) 2011-09-29
IL221510A0 (en) 2012-12-02
MX2012010954A (es) 2012-11-23
BR112012021579A2 (pt) 2019-09-24
ES2688574T3 (es) 2018-11-05
HK1179946A1 (en) 2013-10-11
ZA201208067B (en) 2014-03-26
AU2011231508B2 (en) 2014-07-31
SG183837A1 (en) 2012-10-30
CN102834379A (zh) 2012-12-19
JP2013523621A (ja) 2013-06-17
IL221510A (en) 2016-02-29
EP2552891B1 (en) 2018-08-08
RU2551423C2 (ru) 2015-05-27
JP5830519B2 (ja) 2015-12-09

Similar Documents

Publication Publication Date Title
US8501153B2 (en) Active enantiomer
KR101886879B1 (ko) Ｐｂｒ 리간드로서의 트리시클릭 인돌 유도체
US9314541B2 (en) In vivo imaging method for cancer
US9168317B2 (en) In vivo imaging method of mood disorders
CN110229093B (zh) 用于体内成像的咔唑化合物
HK1179946B (en) Tricyclic indole derivatives as pbr ligands
US9220795B2 (en) Indole derivatives
HK1167393B (en) Tricyclic indole derivates as pbr ligands

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8